Efficacy of Bifeprunox in Patients With Schizophrenia

Launched by H. LUNDBECK A/S · Apr 9, 2008

Keywords

ClinConnect Summary

Schizophrenia is a serious and disabling mental disorder that affects approximately 1% of the world's population. There are a number of antipsychotic drugs in use but none is ideal, in particular because their safety profile is complex and their effectiveness is limited. In particular, after having overcome acute exacerbations many patients continue to experience significant symptoms that prevent an adequate functioning. In the current study, patients suffering from schizophrenia and currently in a post-acute maintenance phase of the disease will be included. Non-treatment resistant patient...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Main inclusion criteria
• • The subject has a primary diagnosis of schizophrenia
• • The subject experiences clinically significant symptoms
• • The subject's medication remained stable for 8 weeks prior to screening
• • The subject is currently in the post-acute maintenance phase of his/her disease
• Exclusion Criteria:
• • Main exclusion criteria
• • The subject is at significant risk of suicide
• • The subject is treatment resistant
• • The subject has experienced an acute exacerbation within 8 weeks prior screening
• • The subject is unlikely to comply with the protocol
• • The subject has a current diagnosis or a history of substance abuse